Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q4 2022 Update

Apr. 07, 2023 6:14 AM ETGLD, IEMG, IVV, JNJ, KO, MCD, PEP, PG, SBUX, VEIEX, VEMAX, VEMIX, VEMRX, VWO, WMT, SPY, COST, PDD, CVS, ABT, MDLZ
John Vincent profile picture
John Vincent
22.9K Followers

Summary

  • Bridgewater Associates’ 13F portfolio value decreased from ~$19.75B to ~$18.32B this quarter.
  • They increased Berkshire Hathaway and Estee Launder while reducing Procter & Gamble, Johnson & Johnson, PepsiCo, and Coca-Cola.
  • The top three individual stock positions are Procter & Gamble, Johnson & Johnson, and PepsiCo and they add up to ~12% of the portfolio.

TechCrunch Disrupt San Francisco 2019 - Day 1

Kimberly White

This article is part of a series that provides an ongoing analysis of the changes made to Bridgewater Associates' 13F portfolio on a quarterly basis. It is based on their regulatory 13F Form filed on 2/13/2023. Please visit our

Ray Dalio - Bridgewater Associates' Q4 2022 13F Report Q/Q Comparison

Ray Dalio - Bridgewater Associates' Q4 2022 13F Report Q/Q Comparison (John Vincent (author))

This article was written by

John Vincent profile picture
22.9K Followers
Focused on analyzing 13F reports & building tools to help DIY investors generate absolute returns through exploiting inefficiency, volatility, and momentum.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.